FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:RASAL2-ZNF695

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: RASAL2-ZNF695
FusionPDB ID: 72435
FusionGDB2.0 ID: 72435
HgeneTgene
Gene symbol

RASAL2

ZNF695

Gene ID

9462

57116

Gene nameRAS protein activator like 2zinc finger protein 695
SynonymsNGAPSBZF3
Cytomap

1q25.2

1q44

Type of geneprotein-codingprotein-coding
Descriptionras GTPase-activating protein nGAPRASAL2/ACVR1 fusionRas protein activator like 1zinc finger protein 695zinc finger protein SBZF3
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000367649, ENST00000448150, 
ENST00000462775, ENST00000465723, 
ENST00000498046, ENST00000339986, 
ENST00000487338, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score19 X 13 X 10=24703 X 2 X 4=24
# samples 204
** MAII scorelog2(20/2470*10)=-3.62643913669732
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/24*10)=0.736965594166206
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: RASAL2 [Title/Abstract] AND ZNF695 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: RASAL2 [Title/Abstract] AND ZNF695 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)RASAL2(178063829)-ZNF695(247109129), # samples:1
Anticipated loss of major functional domain due to fusion event.RASAL2-ZNF695 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
RASAL2-ZNF695 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
RASAL2-ZNF695 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
RASAL2-ZNF695 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:178063829/chr1:247109129)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across RASAL2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ZNF695 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000448150RASAL2chr1178063829-ENST00000487338ZNF695chr1247109129-11199664101117236
ENST00000367649RASAL2chr1178063829-ENST00000487338ZNF695chr1247109129-707554166705180

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000448150ENST00000487338RASAL2chr1178063829-ZNF695chr1247109129-0.280361920.71963805
ENST00000367649ENST00000487338RASAL2chr1178063829-ZNF695chr1247109129-0.6246510.37534901

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for RASAL2-ZNF695

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
RASAL2chr1178063829ZNF695chr1247109129554129ESVCQQQSWVRVYGSSRRPSSCFEDP
RASAL2chr1178063829ZNF695chr1247109129966185ESVCQQQSWVRVYGSSRRPSSCFEDP

Top

Potential FusionNeoAntigen Information of RASAL2-ZNF695 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
RASAL2-ZNF695_178063829_247109129.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
RASAL2-ZNF695chr1178063829chr1247109129554HLA-A30:08RVYGSSRRP0.98380.76321019

Top

Potential FusionNeoAntigen Information of RASAL2-ZNF695 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
RASAL2-ZNF695_178063829_247109129.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
RASAL2-ZNF695chr1178063829chr1247109129554DRB1-1510QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB1-1510QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB1-1537QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB1-1537QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0101QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0101QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0102QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0103QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0103QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0103QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0104QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0104QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0105QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0105QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0106QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0106QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0106QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0106SWVRVYGSSRRPSSC722
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0108NQQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0111QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0111QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0111QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0113QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0113QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0114QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0114QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0202QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0202QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0202QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0202SWVRVYGSSRRPSSC722
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0203QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0203QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0203QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0203SWVRVYGSSRRPSSC722
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0204QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0204QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0204QQQSWVRVYGSSRRP419
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0204SWVRVYGSSRRPSSC722
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0205QSWVRVYGSSRRPSS621
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0205QQSWVRVYGSSRRPS520
RASAL2-ZNF695chr1178063829chr1247109129554DRB5-0205QQQSWVRVYGSSRRP419

Top

Fusion breakpoint peptide structures of RASAL2-ZNF695

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7593QSWVRVYGSSRRPSRASAL2ZNF695chr1178063829chr1247109129554

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of RASAL2-ZNF695

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7593QSWVRVYGSSRRPS-7.9962-8.1096
HLA-B14:023BVN7593QSWVRVYGSSRRPS-5.70842-6.74372
HLA-B52:013W397593QSWVRVYGSSRRPS-6.83737-6.95077
HLA-B52:013W397593QSWVRVYGSSRRPS-4.4836-5.5189
HLA-A11:014UQ27593QSWVRVYGSSRRPS-10.0067-10.1201
HLA-A11:014UQ27593QSWVRVYGSSRRPS-9.03915-10.0745
HLA-A24:025HGA7593QSWVRVYGSSRRPS-6.56204-6.67544
HLA-A24:025HGA7593QSWVRVYGSSRRPS-5.42271-6.45801
HLA-B44:053DX87593QSWVRVYGSSRRPS-7.85648-8.89178
HLA-B44:053DX87593QSWVRVYGSSRRPS-5.3978-5.5112
HLA-A02:016TDR7593QSWVRVYGSSRRPS-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of RASAL2-ZNF695

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
RASAL2-ZNF695chr1178063829chr12471091291019RVYGSSRRPGGGTGTACGGGTCCAGTCGTCGACCAT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
RASAL2-ZNF695chr1178063829chr1247109129419QQQSWVRVYGSSRRPAGCAACAGAGCTGGGTCCGGGTGTACGGGTCCAGTCGTCGACCAT
RASAL2-ZNF695chr1178063829chr1247109129520QQSWVRVYGSSRRPSAACAGAGCTGGGTCCGGGTGTACGGGTCCAGTCGTCGACCATCGA
RASAL2-ZNF695chr1178063829chr1247109129621QSWVRVYGSSRRPSSAGAGCTGGGTCCGGGTGTACGGGTCCAGTCGTCGACCATCGAGCT
RASAL2-ZNF695chr1178063829chr1247109129722SWVRVYGSSRRPSSCGCTGGGTCCGGGTGTACGGGTCCAGTCGTCGACCATCGAGCTGCT

Top

Information of the samples that have these potential fusion neoantigens of RASAL2-ZNF695

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCARASAL2-ZNF695chr1178063829ENST00000367649chr1247109129ENST00000487338TCGA-B6-A0RS-01A

Top

Potential target of CAR-T therapy development for RASAL2-ZNF695

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to RASAL2-ZNF695

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to RASAL2-ZNF695

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource